Journal Article Ahead of print
PubMed: 41766356 DOI: 10.1111/ajco.70092
Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025.
Asia Pac J Clin Oncol
Authors: Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae-Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M C Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, Ian D Davis
Affiliations
- Department of Urology, National University Hospital, Singapore, Singapore.
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Division of Cancer Surgery, Department of Genitourinary Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Urology, Christchurch Public Hospital, Christchurch, New Zealand.
- Department of Urology, Singapore General Hospital, Singapore, Singapore.
- Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
- Department of Medicine, Faculty of Medicine and Health, Institut Teknologi Sepuluh Nopember, Surabaya, Indonesia.
- Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
- Department of Urology, Center for Urological Cancer, National Cancer Center, Goyang, South Korea.
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
- Department of Urology/Uro-oncology, Ushakal Abhinav Institute of Medical Sciences, Sangli, India.
- Department of Urology, Chinese General Hospital and Medical Center, Manila, Philippines.
- Department of Surgery, Chiang Mai University, Chiang Mai, Thailand.
- Department of Radiation Oncology, Tata Medical Center, Kolkata, India.
- SH Ho Urology Centre, The Chinese University of Hong Kong, Ma Liu Shu, Hong Kong.
- Department of Diagnostic Imaging, National University Hospital, Singapore, Singapore.
- Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
- Department of Urology, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan.
- Department of Clinical Oncology, The Chinese University of Hong Kong, Ma Liu Shu, Hong Kong.
- STARS Education and Research Alliance, Metro North Health and The University of Queensland, Herston, Queensland, Australia.
- Department of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
- Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore.
- Department of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore.
- Department of Urology, Altunizade Hospital, Acibadem M.A. Aydinlar University, Istanbul, Türkiye.
- Department of Urology, Binh Dan Hospital, Ho Chi Minh City, Vietnam.
- Department of Haematology Oncology, National University Hospital, Singapore, Singapore.
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Monash University, Melbourne, Victoria, Australia.
- Eastern Health, Melbourne, Victoria, Australia.
Abstract
AIM
The aim of the fourth Asia-Pacific Advanced Prostate Cancer Symposium (APAC APCS 2025) was to discuss the application in the Asia-Pacific (APAC) region of outcomes from the fifth Advanced Prostate Cancer Consensus Conference (APCCC 2024).
METHODS
The one-day symposium in September 2025 brought together 28 experts from 15 APAC countries or regions. The symposium covered five topics: (1) high-risk localized/locally advanced prostate cancer; (2) prostate-specific antigen persistence and recurrence; (3) radioligand therapy; (4) genetics and genomics; (5) bone protection and other aspects of supportive care. Presymposium polling and expert presentations prefaced in-depth discussions to gather insights on current practice and challenges in the region.
RESULTS
APAC APCS 2025 highlighted the increasing complexities in diagnosis and management of advanced prostate cancer and the impact on practice of variations in access and cost. Panelists described variations in access and reimbursement for PSMA-PET/CT, abiraterone, androgen receptor pathway inhibitors, 177Lu-PSMA, and bone-protecting agents. While most panelists reported access to nuclear medicine expertise, access to genetic counsellors continues to be limited in many parts of the region. Discussions highlighted creative approaches used to minimize costs while maximizing options for patients.
CONCLUSION
APAC Advanced Prostate Cancer Symposia are important forums for discussing APAC-specific considerations in areas where clinical evidence is evolving. In an era of increasingly sophisticated technologies, discussions highlight the importance of not losing sight of patient and clinical factors in decision-making. Multidisciplinary and personalized management is critical, along with the need for locally relevant data to inform APAC-specific guidelines.
MeSH
Neoplasms, Prostate, Prostatic Neoplasms